Publication Name	World Journal of Cardiology
Manuscript ID	74514
Country	India

Received	2021-12-26 21:18
Peer-Review Started	2021-12-26 21:20
To Make the First Decision
Return for Revision	2022-03-16 01:59
Revised	2022-03-17 23:22
Second Decision	2022-05-20 03:08
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-05-23 00:47
Articles in Press	2022-05-23 00:47
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-05-31 11:28
Typeset the Manuscript	2022-06-08 10:38
Publish the Manuscript Online	2022-06-21 01:59

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Opinion Review
Article Title	Metabolic and cardiovascular benefits with SGLT-2 inhibitors and GLP-1 receptor agonists combination therapy in type 2 diabetes
Manuscript Source	Invited Manuscript
All Author List	Awadhesh Kumar Singh and Ritu Singh
Funding Agency and Grant Number
Corresponding Author	Awadhesh Kumar Singh, MBBS, MD, PhD, Consultant Physician-Scientist, Intermediate Editor, Senior Postdoctoral Fellow, Senior Researcher, Department of Diabetes and Endocrinology, G.D Hospital and Diabetes Institute, No. 3 Canal Street, Kolkata 700013, India. draksingh_2001@yahoo.com
Key Words	GLP-1 receptor agonists; SGLT-2 inhibitors; Combination therapy, Metabolic outcomes; Cardiovascular outcomes; Renal outcomes
Core Tip	GLP-1 receptor agonists (GLP-1RA) plus SGLT-2 inhibitors (SGLT-2I) dual therapy causes a greater reduction in HbA1c, body weight, and systolic blood pressure (SBP), compared to either agent alone with similar adverse events. However, lowering of HbA1c, body weight, and SBP with combination therapy appeared to be less, nearly equal, and more than additive, respectively, compared to the sum of either agent alone. Our meta-analysis from 5 cardiovascular outcome trials suggests a similar reduction in major adverse cardiovascular events with dual therapy compared to GLP-1RA or SGLT-2I alone, but an additional benefit in heart failure hospitalization is likely. Future trials are needed to confirm these findings.
Publish Date	2022-06-21 01:59
Citation	Singh AK, Singh R. Metabolic and cardiovascular benefits with SGLT-2 inhibitors and GLP-1 receptor agonists combination therapy in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342
URL	https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm
DOI	https://dx.doi.org/10.4330/wjc.v14.i6.329

Full Article (PDF)	WJC-14-329.pdf
Full Article (Word)	WJC-14-329.docx
Manuscript File	74514_Auto_Edited-HZ-FilipodiaCL-LS_WangTQ.docx
Answering Reviewers	74514-Answering reviewers.pdf
Audio Core Tip	74514-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	74514-Conflict-of-interest statement.pdf
Copyright License Agreement	74514-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	74514-Language certificate.pdf
Supplementary Material	74514-Supplementary material.pdf
Peer-review Report	74514-Peer-review(s).pdf
Scientific Editor Work List	74514-Scientific editor work list.pdf